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INTRODUCTION
Ovarian cancer still has a high mortality rate in de-
veloped and developing countries. There are no exact
data on ovarian cancer incidence and mortality in In-
donesia. A study in 2002 revealed that ovarian cancer
was the third most frequent female cancer in Indone-
sia (829 new cases and 7.77% of all female cancers).1
Another study in 2001 reported that based on patho-
logical reports in 12 cancer registries in Indonesia,
the number of ovarian cancer new cases was 1200 in
1994.2 Surveillance Epidemiology and End Result
(SEER) United States reported that the incidence of
ovarian cancer on 1975 - 2005 was 7.3 per 100,000
and the death rate was 5.0 per 100,000. A total of
21,650 new ovarian cancer cases and 15,520 deaths
were reported in the United States in 2008.3 In the
Netherlands, approximately 1,100 patients were new-
ly diagnosed with ovarian cancer in 2005 and 946
women died as a result of this disease in the same
year.4 Having the high number of mortality and mor-
bidity, it is well established that ovarian cancer cases
which were treated by gynecologic oncologists had
Abstract
Objective: To analyse retrospectively the score of the risk of
malignancy index (RMI) in determining malignancy in the patients
with ovarian mass in Dr. Sardjito Hospital Yogyakarta.
Method: Retrospective analysis.
Results: Ninety patients with complete medical record and
adnexal mass were enrolled in the study from January 2007 to
March 2009. Subjects consisted of 70 patients (77.78%) diagnosed
with malignant ovarian mass and 20 patients with benign mass
(22.22%), More than half of the malignant ovarian mass were serous
carcinomas and at advanced stages (51.43% and 51.43% sub-
sequently). Univariate analysis presented significant difference for
ultrasound score and serum Ca-125 level in identification of ovarian
malignancy, but not with the age or the menopausal status. The per-
formance of RMI (≥ 200 for malignancy) had a sensitivity of 70%,
a specificity of 75%, a positive predictive value of 90.74%, and
negative predictive value of 41.67%. The serum Ca-125 level had a
sensitivity of 81.43%, a specificity of 60%, a positive predictive
value of 87.69%, and a negative predictive value of 48%. The ultra-
sound score had a sensitivity of 65.71%, a specificity of 65%, a
positive predictive value of 86.79%, and a negative predictive value
of 35.14%.
Conclusion: Due to the nature of retrospective study, RMI is re-
liable for identification of malignant and benign ovarian mass im-
prove the management of ovarian mass including referral system
and the decision regarding the approach used during surgery.
[Indones J Obstet Gynecol 2010; 34-3: 131-5]
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Abstrak
Tujuan: Menganalisis indeks risiko keganasan untuk menentu-
kan keganasan ovarium di RS Dr. Sardjito, Yogyakarta.
Metode: Analisis retrospektif.
Hasil: Sembilan puluh pasien dengan massa adneksa dan data
rekam medik yang lengkap dikumpulkan sejak Januari 2007 sampai
Maret 2009 terdiri atas 70 pasien (77,78%) dengan keganasan ova-
rium dan 20 pasien dengan massa jinak (22,22%). Lebih dari sete-
ngah seluruh subyek penelitian menunjukkan histopatologi serous
carcinoma (51,43%) dan berada pada stadium lanjut (51,43%).
Analisis univariat menunjukkan bahwa perbedaan yang signifikan
pada pasien dengan kanker ovarium dan massa jinak ovarium di-
perlihatkan oleh penilaian pemeriksaan ultrasonografi dan peme-
riksaan Ca-125 serum, tetapi tidak pada umur dan status meno-
pause. Pada penelitian ini, RMI menunjukkan sensitivitas 70%, spe-
sifisitas 75%, prediksi positif 90,74%, dan prediksi negatif 41,67%.
Pemeriksaan tumor marker Ca-125 pada serum menunjukkan sen-
sitivitas 81,43%, spesifisitas 60%, prediksi positif 87,69%, dan pre-
diksi negatif 48%. Penilaian hasil pemeriksaan ultrasonografi me-
nunjukkan sensitivitas 65,71%, spesifisitas 65%, prediksi positif
86,79%, dan prediksi negatif 35,14%.
Kesimpulan: Pada penelitian yang bersifat retrospektif ini, RMI
dapat membedakan massa ovarium ganas dan jinak dengan baik.
Hal ini dibutuhkan untuk meningkatkan penanganan massa adneksa
termasuk keputusan merujuk dan keputusan menggunakan pende-
katan onkologi saat dilakukan operasi.
[Maj Obstet Ginekol Indones 2010; 34-3: 131-5]
Kata kunci: indeks risiko keganasan, RMI, kanker ovarium, kar-
sinoma ovarium, malignansi ovarium
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marginally better outcome. A large number of patients
(3,067 patients) were enrolled in a study to compare
the surgery outcomes on ovarian cancer patients ma-
naged by gynecologic oncologists to general gyneco-
logist or general surgeon.5 Beside less morbidities,
surgeries done by gynecologic oncologists also have
better survivals.5,6 Repeated surgery was reported to
be associated not only with younger patients, gemer-
minal tumors, well-differentiated tumors and early
stages but also with the surgeon’s discipline.7
Approach to pelvic mass should be done through
pelvic examination including radiologic examination
and tumor marker in order to differentiate the mass
from benign to malignant tumors. That is necessary to
adequately assess the adnexal mass because the pre-
sumed diagnosis determines the management. More-
over, pelvic mass is the most frequent indicator to
refer the patient to a cancer center or a tertiary center
with gynecologic oncologist attendance. For such rea-
sons improved both specificity and sensitivity diag-
nostic methods are needed.
The risk of malignancy index (RMI) is a simple
scoring system that can be used to assess the adnexal
mass. The RMI scoring system is based on meno-
pausal status, ultrasound and serum concentration of
Ca-125. The scoring provides a better method to as-
sess the adnexal mass especially in the less special-
ized centers compared to single parameter.8-12 Jacobs
et al has developed risk of malignancy index RMI 1
followed by RMI 2 and RMI 3 by Tingulstad et al
and RMI 4 by Yamamoto et al. Except RMI 4 which
uses the tumor size score, all RMIs use the parameter
of the ultrasound findings (U), the menopausal score
(M), and the serum of Ca-125 level (Ca-125).
1. RMI 1 = U x M x Ca-125; a total ultrasound
score of 0 gave U = 0, a score of 1 gave U = 1,
and a score of ≥ 2 gave U = 3. Premenopausal
status gave M = 1 and postmenopausal status
gave M = 3. The serum level of Ca-125 was ap-
plied directly to the calculation.8
2. RMI 2 = U x M x Ca-125; a total ultrasound
score of 0 or 1 gave U = 1, and a score of ≥ 2
yielded U = 4. Premenopausal status gave M = 1
and postmenopausal status gave M = 4. The se-
rum level of Ca-125 was applied directly to the
calculation.10
3. RMI 3 = U x M x Ca-125; a total ultrasound
score of 0 or 1 gave U = 1, and a score of ≥ 2
gave U = 3. Premenopausal status gave M = 1
and postmenopausal status gave M = 3. The se-
rum Ca-125 level was applied directly to the cal-
culation.11
4. RMI 4 = U x M x S x Ca-125, where a total
ultrasound score of 0 or 1 gave U = 1, and a score
of ≥ 2 gave U = 4. Premenopausal status gave M
= 1 and postmenopausal status gave M = 4. A
tumor size (single greatest diameter) of < 7 cm
yielded S = 1, and ≥ 7 cm gave S = 2. The serum
level of Ca-125 was applied directly to the cal-
culation.12
Although the results still differ in many studies,
RMI 3 is generally considered to have the best sen-
sitivity and specificity.12,13 Validation of RMI 3 usage
has been done in several studies.14-16 In this study,
we will further use only RMI 3 to be compared with
the singular parameters; the serum Ca-125 level, me-
nopausal status, and ultrasound score.
METHOD
This study is a retrospective analysis taken from me-
dical record. The clinical data of 90 women with pel-
vic mass were taken from January 1, 2009 to March
1, 2010 at the Obstetrics and Gynecology Department
of Dr. Sardjito Hospital, Yogyakarta. The incomplete
data was excluded. The clinical data include age, the
detail result of ultrasound, preoperative serum Ca-125
level, and the final pathology result of the mass.
The ultrasound was performed abdominally or va-
ginally and the ultrasound score was assigned for the
following features multiloculations, the presence of
solid elements, bilaterality, the presence of ascites, or
the evidence of metastases. An ultrasound score (U)
of 1 was given if none or one of the features was
found, and a score of 3 was given if two or more of
these features were shown. A menopausal score (M)
of 1 or 3 was given to pre- and postmenopausal wo-
men. The level of Ca-125 in serum was calculated di-
rectly to the formula below:
RMI = U x M x Ca-125
The histopathological result determined the final
diagnosis of benign or malignant mass. When a gy-
necological cancer was found, it was staged accor-
ding to the International Federation of Gynecology
and Obstetrics classification.17 All statistical analyses
were performed using the Statistical Package for So-
cial Sciences (SPSS Inc.), Version 15. Mann Whitney
U test was performed for the continuous data and
Pearson chi-square test was used for the dichotomous
data. The sensitivity was defined as the percentage of
patients with malignant ovarian mass having a posi-
tive test result. The specificity was defined as the per-
centage with benign ovarian mass showing negative
results. The positive predictive value was defined as
the percentage of patients with a positive test result
having malignant ovarian mass and the negative pre-
dictive value was defined as the percentage of patients
with a negative test result having benign ovarian
mass. A receiver operating characteristic (ROC) curve
was created to show the relation between sensitivity
and specificity of the RMI, serum Ca-125 level, and
ultrasound score in the discrimination between benign
and malignant ovarian mass.
RESULTS
A total of 90 patients were enrolled in the study, 70
of them (77.78%) were diagnosed with malignant
ovarian mass whereas 20 of them (22.22%) were be-
nign. The distribution of age, menopausal status, ul-
trasound score, and serum Ca-125 level were shown
in Table 1 for the two groups (the groups with benign
and malignant ovarian mass). Univariate analysis was
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done on the two groups. The differences on ultra-
sound score and serum Ca-125 level were significant
between the two groups, but not with the age or the
menopausal status as described in Table 1. Ultrasound
score of 3 were mostly found in malignant patients
as well as higher level of serum Ca-125.
Among patients with malignant ovarian mass, 34
patients (48.57%) were considered to be at early sta-
ges and 36 patients (51.43%) were at advanced stages.
The majority of histopathological result for malignant
mass shown serous adenocarcinoma (51.43%) follow-
ed by mucinous adenocarcinoma (32.29%). The dif-
ferent histology results are listed in Table 2.
The performance of menopausal status, serum Ca-
125 level, ultrasound score and RMI in predicting ma-
lignancy in this study are presented in Table 3. The
cut-off point of RMI (≥ 200) was determined from
previous studies.12-14 In our study, the RMI had a sen-
sitivity of 70%, a specificity of 75%, a positive pre-
dictive value of 90.74%, and negative predictive value
of 41.67%. The serum Ca-125 level had a sensitivity
of 81.43%, a specificity of 60%, a positive predictive
value of 87.69%, and a negative predictive value of
48%. The ultrasound score had a sensitivity of 65.71%,
a specificity of 65%, a positive predictive value of
86.79%, and a negative predictive value of 35.14%.
The performances of RMI, serum Ca-125 level, age
and ultrasound score are presented individually in re-
ceiver operator characteristic curves (Figure 1).
DISCUSSION
The probability of malignancy should always be taken
into consideration in approach to adnexal mass. Mo-
dalities to differentiate malignancy in ovarian mass
include ultrasound examination and serum Ca-125 le-
vel examination. Since the first time introduced by
Jacobs et al8, RMI has continuously shown to have
the ability in improving malignancy identification of
ovarian mass.10,11,18 Although this study shows lower
sensitivity and specificity compared to previous stu-
dies12-14,19, it still confirmed that the combination of
RMI’s sensitivity, specificity, positive predictive va-
lue and negative predictive value were better than the
same combination parameters for serum Ca-125 level
and ultrasound score to discriminate malignant and
benign adnexal mass in Dr. Sardjito Hospital. This
might due to lesser subjects with benign ovarian mass
compared to the previous studies.
Table 2. Distribution of Diagnosis and Stages in 90 Patients
with Ovarian Masses.
Diagnosis n (%)
Ovarian cancer
Stage I
Stage II
Stage III
Stage IV
22 (31.43)
12 (17.14)
32 (45.71)
 4 ( 5.72)
Histopathology results of malignant ovarian mass
Serous cystadenocarcinoma
Mucinous cystadenocarcinoma
Endometrioid carcinoma
Clear cell carcinoma
Undifferentiated carcinoma
32 (51.43)
24 (34.29)
 5 ( 7.14)
 3 ( 4.29)
 2 ( 2.86)
Total malignant ovarian mass 70 (77.78)
Total benign ovarian mass 20 (22.22)
A high sensitivity was detected in serum Ca-125
level, yet it was not accompanied by better specificity
just like previous studies.12-14 Ca-125 level could in-
crease not only in ovarian malignancy but also in en-
dometriosis, pelvic inflammatory diseases, other be-
nign ovarian cysts, and other malignancies such as
colon cancer.
In Indonesian setting of health care, laboratories
are often not equipped with an adequate tumor marker
panel. The ultrasonographer and the ultrasound ma-
chine are also not available in smaller or rural hospi-
Table 1. Distribution of age, menopausal status, ultrasound score and serum Ca-125 levels in patients with benign ovarian
mass (n=20) and malignant ovarian mass (n=70).
Malignant ovarian mass
(n = 70)
Benign ovarian mass
(n = 20)
Significance level
 (p)
Age (years)
Median (range) 47.50 (15 - 76) 44.00 (19 - 72) 0.191a
Menopausal status
Menopause n (%)
Not-menopause n (%)
38 (73.1)
32 (84.2)
14 (26.9)
 6 (15.8)
0.210b
Ultrasound score
Score 3 n (%)
Score 1 n (%)
46 (64.9)
24 (86.8)
 7 (35.1)
13 (13.2)
0.014b
Serum Ca-125 level (U/ml)
Mean
Median (range)
Minimum
Maximum
545.57
195.73
  6.87
15258     
116.3 
 31.31
  3.59
600   
0.001a
aMann-Whitney U test
bPearson X2 test
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tals. Therefore, RMI can only be performed at tertiary
hospitals. RMI can help determining whether the pa-
tient should be operated by a gynecologic oncologist
or a general gynecologist.
CONCLUSION
Risk of malignancy index is a scoring system using
menopausal status, ultrasound, and serum Ca-125
level to discriminate malignant adnexal mass from be-
nign ones. In this study, RMI is reliable to identify
malignant and benign ovarian mass in Dr. Sardjito
Hospital. This scoring system can be used to improve
the management of ovarian mass including the ur-
gency to refer and the decision regarding the approach
used during surgery. Since it is well established that
the management of this malignancy was conducted
better in the cancer center with oncologists.
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